PT Indofarma Tbk Logo

PT Indofarma Tbk

INAF.JK

(1.2)
Stock Price

126 IDR

-29.39% ROA

6154.65% ROE

-3.65x PER

Market Cap.

1.596.124.050.000 IDR

-732.6% DER

0% Yield

-63.81% NPM

PT Indofarma Tbk Stock Analysis

PT Indofarma Tbk Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PT Indofarma Tbk Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (-41.95x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (-2261%), which means it has a small amount of debt compared to the ownership it holds

3 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (281.367) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

4 ROE

Negative ROE (-455.7%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-29.48%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

10 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

11 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

PT Indofarma Tbk Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PT Indofarma Tbk Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

PT Indofarma Tbk Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PT Indofarma Tbk Revenue
Year Revenue Growth
2005 684.039.648.705
2006 1.026.675.533.939 33.37%
2007 1.273.162.479.164 19.36%
2008 1.478.585.255.395 13.89%
2009 1.125.055.390.936 -31.42%
2010 1.047.918.156.470 -7.36%
2011 1.203.466.970.652 12.93%
2012 1.156.050.256.720 -4.1%
2013 1.337.498.191.710 13.57%
2014 1.381.436.578.115 3.18%
2015 1.621.898.667.657 14.83%
2016 1.674.702.722.328 3.15%
2017 1.631.317.499.096 -2.66%
2018 1.592.979.941.258 -2.41%
2019 1.359.175.249.655 -17.2%
2020 1.715.587.654.399 20.77%
2021 2.901.986.532.879 40.88%
2022 1.144.108.230.742 -153.65%
2023 326.947.411.912 -249.94%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PT Indofarma Tbk Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PT Indofarma Tbk General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 57.565.255.377
2006 66.212.433.120 13.06%
2007 77.485.571.553 14.55%
2008 80.026.484.368 3.18%
2009 83.146.833.682 3.75%
2010 92.084.629.904 9.71%
2011 110.641.804.738 16.77%
2012 40.894.059.690 -170.56%
2013 57.821.781.404 29.28%
2014 31.954.411.457 -80.95%
2015 28.761.955.152 -11.1%
2016 35.359.404.294 18.66%
2017 28.766.502.760 -22.92%
2018 30.896.858.741 6.9%
2019 31.802.650.985 2.85%
2020 41.158.084.045 22.73%
2021 45.749.651.185 10.04%
2022 42.940.336.304 -6.54%
2023 20.860.472.680 -105.85%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PT Indofarma Tbk EBITDA
Year EBITDA Growth
2005 32.920.306.833
2006 59.186.522.891 44.38%
2007 38.146.170.731 -55.16%
2008 39.319.014.008 2.98%
2009 51.440.322.992 23.56%
2010 59.732.654.371 13.88%
2011 103.999.718.253 42.56%
2012 85.144.269.236 -22.15%
2013 -39.811.305.017 313.87%
2014 51.273.748.985 177.64%
2015 62.540.114.207 18.01%
2016 44.450.956.462 -40.69%
2017 22.143.023.352 -100.74%
2018 -9.482.702.480 333.51%
2019 24.718.909.711 138.36%
2020 101.652.489.690 75.68%
2021 71.480.822.442 -42.21%
2022 -440.575.151.552 116.22%
2023 -248.802.220.860 -77.08%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PT Indofarma Tbk Gross Profit
Year Gross Profit Growth
2005 199.271.012.653
2006 255.957.002.117 22.15%
2007 289.954.334.483 11.73%
2008 333.402.834.395 13.03%
2009 304.635.812.804 -9.44%
2010 318.464.313.193 4.34%
2011 396.184.357.869 19.62%
2012 367.895.645.035 -7.69%
2013 337.567.310.511 -8.98%
2014 312.426.176.597 -8.05%
2015 330.054.446.623 5.34%
2016 336.908.968.011 2.03%
2017 282.813.283.645 -19.13%
2018 284.219.823.451 0.49%
2019 250.360.113.159 -13.52%
2020 400.599.780.823 37.5%
2021 451.653.984.366 11.3%
2022 -110.108.711.011 510.19%
2023 -13.463.467.604 -717.83%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PT Indofarma Tbk Net Profit
Year Net Profit Growth
2005 9.594.742.649
2006 15.240.675.138 37.05%
2007 11.076.807.048 -37.59%
2008 5.031.898.680 -120.13%
2009 2.125.637.967 -136.72%
2010 12.546.644.388 83.06%
2011 36.919.316.551 66.02%
2012 42.384.956.906 12.9%
2013 -54.222.344.142 178.17%
2014 1.166.073.487 4749.99%
2015 6.566.935.986 82.24%
2016 -17.366.640.817 137.81%
2017 -46.282.940.175 62.48%
2018 -32.735.901.428 -41.38%
2019 7.960.962.724 511.21%
2020 27.580.910 -28764.03%
2021 -37.571.241.226 100.07%
2022 -428.487.671.595 91.23%
2023 -285.415.415.196 -50.13%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PT Indofarma Tbk Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 3
2006 5 25%
2007 4 -33.33%
2008 0 0%
2009 1 0%
2010 4 100%
2011 12 63.64%
2012 14 15.38%
2013 -18 176.47%
2014 2 950%
2015 2 0%
2016 -6 140%
2017 -15 64.29%
2018 -11 -40%
2019 3 600%
2020 0 0%
2021 -12 100%
2022 -138 91.3%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PT Indofarma Tbk Free Cashflow
Year Free Cashflow Growth
2005 -64.070.483.192
2006 71.469.702.925 189.65%
2007 80.648.220.609 11.38%
2008 -202.715.549.384 139.78%
2009 18.910.314.793 1171.98%
2010 18.142.959.514 -4.23%
2011 24.794.128.371 26.83%
2012 -47.981.898.604 151.67%
2013 -178.225.035.659 73.08%
2014 92.678.925.374 292.3%
2015 111.331.095.044 16.75%
2016 -377.597.165.317 129.48%
2017 52.310.453.840 821.84%
2018 -117.159.661.248 144.65%
2019 18.193.988.941 743.95%
2020 32.770.612.735 44.48%
2021 71.495.333.562 54.16%
2022 -423.328.992.307 116.89%
2023 -88.884.192.581 -376.27%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PT Indofarma Tbk Operating Cashflow
Year Operating Cashflow Growth
2005 -54.871.009.457
2006 73.151.865.243 175.01%
2007 83.418.335.788 12.31%
2008 -187.307.305.048 144.54%
2009 40.557.994.677 561.83%
2010 23.713.155.869 -71.04%
2011 29.396.516.728 19.33%
2012 -40.914.557.262 171.85%
2013 -141.616.973.090 71.11%
2014 148.726.901.608 195.22%
2015 134.284.985.660 -10.75%
2016 -317.962.543.661 142.23%
2017 147.184.447.849 316.03%
2018 -70.390.895.931 309.1%
2019 20.790.922.347 438.57%
2020 46.547.903.553 55.33%
2021 92.899.478.946 49.89%
2022 -409.853.009.714 122.67%
2023 -86.826.681.678 -372.04%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PT Indofarma Tbk Capital Expenditure
Year Capital Expenditure Growth
2005 9.199.473.735
2006 1.682.162.318 -446.88%
2007 2.770.115.179 39.27%
2008 15.408.244.336 82.02%
2009 21.647.679.884 28.82%
2010 5.570.196.355 -288.63%
2011 4.602.388.357 -21.03%
2012 7.067.341.342 34.88%
2013 36.608.062.569 80.69%
2014 56.047.976.234 34.68%
2015 22.953.890.616 -144.18%
2016 59.634.621.656 61.51%
2017 94.873.994.009 37.14%
2018 46.768.765.317 -102.86%
2019 2.596.933.406 -1700.92%
2020 13.777.290.818 81.15%
2021 21.404.145.384 35.63%
2022 13.475.982.593 -58.83%
2023 2.057.510.903 -554.97%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PT Indofarma Tbk Equity
Year Equity Growth
2005 265.245.146.779
2006 280.485.821.917 5.43%
2007 291.562.628.966 3.8%
2008 296.594.527.646 1.7%
2009 298.720.165.595 0.71%
2010 311.266.809.984 4.03%
2011 609.192.392.975 48.91%
2012 650.100.577.219 6.29%
2013 590.792.019.280 -10.04%
2014 591.958.092.767 0.2%
2015 592.705.032.524 0.13%
2016 575.753.991.513 -2.94%
2017 526.408.631.406 -9.37%
2018 496.646.859.858 -5.99%
2019 504.935.327.036 1.64%
2020 430.326.476.519 -17.34%
2021 508.309.909.506 15.34%
2022 86.348.511.713 -488.67%
2023 -105.356.335.537 181.96%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PT Indofarma Tbk Assets
Year Assets Growth
2005 518.823.729.815
2006 686.937.377.885 24.47%
2007 1.009.437.678.208 31.95%
2008 965.811.675.903 -4.52%
2009 728.034.877.647 -32.66%
2010 733.957.862.391 0.81%
2011 1.114.901.669.774 34.17%
2012 1.188.618.790.410 6.2%
2013 1.294.510.669.195 8.18%
2014 1.248.343.275.406 -3.7%
2015 1.533.708.564.241 18.61%
2016 1.381.633.321.120 -11.01%
2017 1.529.874.782.290 9.69%
2018 1.442.350.608.575 -6.07%
2019 1.383.935.194.386 -4.22%
2020 1.713.334.658.849 19.23%
2021 2.011.879.396.142 14.84%
2022 1.534.000.446.508 -31.15%
2023 1.491.062.009.957 -2.88%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PT Indofarma Tbk Liabilities
Year Liabilities Growth
2005 253.578.088.785
2006 406.451.033.454 37.61%
2007 717.874.312.553 43.38%
2008 669.216.334.511 -7.27%
2009 429.313.361.761 -55.88%
2010 422.689.679.146 -1.57%
2011 505.707.835.106 16.42%
2012 538.516.613.421 6.09%
2013 703.717.301.306 23.48%
2014 656.380.082.911 -7.21%
2015 940.999.667.497 30.25%
2016 805.876.240.489 -16.77%
2017 1.003.464.884.586 19.69%
2018 945.703.748.717 -6.11%
2019 878.999.867.350 -7.59%
2020 1.283.008.182.330 31.49%
2021 1.503.569.486.636 14.67%
2022 1.447.651.934.795 -3.86%
2023 1.596.418.345.494 9.32%

PT Indofarma Tbk Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
220.99
Net Income per Share
-141.02
Price to Earning Ratio
-3.65x
Price To Sales Ratio
2.33x
POCF Ratio
-3.7
PFCF Ratio
-3.74
Price to Book Ratio
-15.15
EV to Sales
3.15
EV Over EBITDA
-4.5
EV to Operating CashFlow
-5.01
EV to FreeCashFlow
-5.06
Earnings Yield
-0.27
FreeCashFlow Yield
-0.27
Market Cap
1.596 Bil.
Enterprise Value
2.158 Bil.
Graham Number
328.4
Graham NetNet
-319.5

Income Statement Metrics

Net Income per Share
-141.02
Income Quality
1.4
ROE
61.55
Return On Assets
-0.29
Return On Capital Employed
-1.49
Net Income per EBT
0.81
EBT Per Ebit
1.09
Ebit per Revenue
-0.73
Effective Tax Rate
0.19

Margins

Sales, General, & Administrative to Revenue
0.05
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.26
Operating Profit Margin
-0.73
Pretax Profit Margin
-0.79
Net Profit Margin
-0.64

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-139.03
Free CashFlow per Share
-137.54
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.01
Capex to Depreciation
0.67
Return on Invested Capital
-0.6
Return on Tangible Assets
-0.29
Days Sales Outstanding
170.42
Days Payables Outstanding
206.88
Days of Inventory on Hand
103.04
Receivables Turnover
2.14
Payables Turnover
1.76
Inventory Turnover
3.54
Capex per Share
1.48

Balance Sheet

Cash per Share
78,99
Book Value per Share
-33,99
Tangible Book Value per Share
-35.21
Shareholders Equity per Share
-33.99
Interest Debt per Share
264.5
Debt to Equity
-7.33
Debt to Assets
0.52
Net Debt to EBITDA
-1.17
Current Ratio
0.71
Tangible Asset Value
-109 Bil.
Net Current Asset Value
-779 Bil.
Invested Capital
-7.33
Working Capital
-339 Bil.
Intangibles to Total Assets
0
Average Receivables
323 Bil.
Average Payables
494 Bil.
Average Inventory
250060132520.5
Debt to Market Cap
0.48

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PT Indofarma Tbk Dividends
Year Dividends Growth
2001 12
2002 20 36.84%
2013 1 -1800%

PT Indofarma Tbk Profile

About PT Indofarma Tbk

PT Indofarma Tbk, together with its subsidiaries, manufactures and markets pharmaceutical products in Indonesia. The company trades in and distributes drugs, medical devices, medical supplies, extracts, and herbals; and operates laboratory. It also provides COVID-19 test services, including rapid diagnostic test antigen; reverse transcription polymerase chain reaction, and genose. The company also exports its products. The company was formerly known as PT Indofarma (Persero) Tbk. PT Indofarma Tbk was founded in 1918 and is headquartered in Bekasi, Indonesia. PT Indofarma Tbk operates as a subsidiary of PT. Bio Farma.

CEO
Mr. Jejen Nugraha
Employee
1.086
Address
Jalan Indofarma No. 1
Bekasi, 17530

PT Indofarma Tbk Executives & BODs

PT Indofarma Tbk Executives & BODs
# Name Age
1 Mr. Warjoko Sumedi
Corporate Secretary
70
2 Mr. Ariesta Krisnawan
Director of Finance, Risk Management & HR and Director
70
3 Mr. Jejen Nugraha
Production & Supply Chain Director and Director
70
4 - Yeliandriani
President Director
70
5 Dr. Andi Prazos Apt, M.M.
Director of Operations & Director
70
6 Mr. Sigit Prakosa C.A., S.E.
Head of Internal Audit Unit
70
7 Ms. Weny Maulatsih
Secretary of Board of Commissioners
70

PT Indofarma Tbk Competitors